Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04716803 |
Recruitment Status :
Recruiting
First Posted : January 20, 2021
Last Update Posted : January 26, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteo Arthritis Knee | Biological: Bone Marrow Aspirate Concentrate Device: Angel Concentrated Platelet Rich Plasma (cPRP) System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis |
Actual Study Start Date : | July 8, 2020 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Bone marrow aspiration concentrate using the Angel System
Bone marrow aspirate concentrate (BMAC) will be administered via injection to the knee of interest on day 14 of the study. Bone marrow aspiration will be concentrated using the Angel System. |
Biological: Bone Marrow Aspirate Concentrate
Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
Other Name: BMAC Device: Angel Concentrated Platelet Rich Plasma (cPRP) System Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
Other Name: The Angel System |
- Patients with at least one severe adverse event [ Time Frame: End of Study (12 months) ]The number of life-threatening severe adverse events as determined by the standard FDA guidelines for adverse events that are deemed to be related to autologous BMAC concentrated by the Angel System and delivered via intra-articular injection into the knee.
- Structural change in knee from baseline measured by the VAS (Visual Analog Scale) in the American College of Rheumatology/Knee Osteoarthritis Assessment Scale (ACR/KOAS). [ Time Frame: End of study (12 months) ]The VAS ranges from 0 to 100 with 0 indicating no damage and higher scores indicating more severe damage.
- Self reported health from baseline through end of study measured by the 36-Item Short Form Survey Instrument (SF-36) Health Survey and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). [ Time Frame: End of study (12 months) ]SF-36 scores are measured via ranges from 0 to 100.
- Rheumatic disease characterization [ Time Frame: End of study (12 months) ]Biological samples (blood, urine, synovial tissue) are characterized via molecular and histological analysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Kellgren Lawrence radiographic grade IV
- Need for a total knee arthroscopy by the patients primary care provider/or orthopedist.
- Persistent pain in target knee that is unresponsive to standard of care including acetametaphine, non-steroidal anti-inflammatory drugs, physical therapy and/or intraarticular corticosteroids and/or hyaluronic acid preparations.
- Males or females aged 45-75.
Exclusion Criteria:
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04716803
Contact: Kenneth Kalunian, MD | 858-246-2381 | kkalunian@health.ucsd.edu |
United States, California | |
University of California San Diego Koman Outpatient Pavilion | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Karen Cuervo, BS 858-249-3038 kcuervo@health.ucsd.edu | |
Principal Investigator: Kenneth Kalunian, MD |
Responsible Party: | Kenneth Kalunian, Professor of Medicine, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT04716803 |
Other Study ID Numbers: |
180916 |
First Posted: | January 20, 2021 Key Record Dates |
Last Update Posted: | January 26, 2022 |
Last Verified: | January 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
moderate to severe knee osteoarthritis total knee replacement bone marrow stem cell-based therapy arthroscopy |
Osteoarthritis Osteoarthritis, Knee Arthritis |
Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |